Screening and prostate-cancer mortality in a randomized European study.
By F. Schröder, J. Hugosson, M. Roobol, T. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Luján, Hans Lilja, M. Zappa and 13 more. New England Journal of Medicine, 2009
4,009 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/60faebae403a5c348cb3ad44b9fb06aa4e3648d7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities (2016, background): “Results from a US-based randomized trial indicated no reduction in prostate cancer mortality as a result of PSA testing, while two European trials showed a modest benefit.(102-104) Studies also suggest that black men are less likely to receive surgical treatment than white men with similar disease c”
- Epidemiology of Prostate Cancer (2019, background): “However, in the USA, a recent randomized controlled trial failed to demonstrate benefits of PSA testing in decreasing prostate cancer deaths, although another research study done in Europe showed benefits of PSA testing [29, 30].”
- Genetics and biology of prostate cancer (2018, background): “Despite the widespread use of PSA screening, four out of five recent randomized clinical trials showed little or no improvement in mortality associated with aggressive treatment of inherently benign disease (Andriole et al. 2009; Schroder et al. 2009, 2012; Ilic et al. 2013).”
- Computer-Aided Detection of Prostate Cancer in MRI (2014, background): “to reduce prostate cancer mortality by 20%–30% [2].”